ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Platelets as regulators of cancer immunity: mechanisms and therapeutic perspectives.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Platelets correspond to one of the most abundant components of the blood and shape the tumor microenvironment, modulate antitumor immune responses, and influence clinical outcomes in cancer patients. Recent studies have expanded our understanding of the mechanisms underlying platelet-immune interactions in cancer, including antigen presentation, immune cell activation, and immunosuppressive signaling. Consequently, platelet-based and platelet-targeted therapies have emerged as promising strategies for enhancing antitumor immunity and improving responses to immunotherapy. However, specifically targeting tumor-educated platelets while minimizing adverse effects, particularly bleeding complications, remains a major challenge. In this review, we summarize the current evidence supporting the dual role of platelets in cancer immunity and discuss how engineered platelets may be leveraged to optimize therapeutic outcomes, highlighting their potential clinical applications and the integration of platelet-targeted approaches into next-generation cancer immunotherapies.
Indexed as
Identifiers
42554924What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.